Abstract
Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker.
Keywords: Insulin resistance, lipolysi, tobacco smoking, nicotine
Current Pharmaceutical Design
Title: Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Volume: 16 Issue: 23
Author(s): Amalia Gastaldelli, Franco Folli and Silvia Maffei
Affiliation:
Keywords: Insulin resistance, lipolysi, tobacco smoking, nicotine
Abstract: Tobacco smoking is the most important preventable cause of cardiovascular disease. In this paper we review current epidemiological and pathophysiological evidence linking smoking with cardiovascular and metabolic diseases. Among the effects of smoking there is the alteration of lipid metabolism through the increase in lipolysis, insulin resistance and tissue lipotoxicity. Smoking is both prothrombotic and atherogenic. As an effect, the risk of acute myocardial infarction, sudden cardiac death, stroke, aortic aneurysm and peripheral vascular disease is increased. Even very low doses of exposure increase the risk of cardiovascular disease (CVD) and metabolic alterations. On the other hand, smoking cessation restores, at least in part, lipid metabolism and the benefits can be observed already after a short period of abstinence from smoking, although it occurs several years before the risks approach those of the never-smoker.
Export Options
About this article
Cite this article as:
Gastaldelli Amalia, Folli Franco and Maffei Silvia, Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk, Current Pharmaceutical Design 2010; 16 (23) . https://dx.doi.org/10.2174/138161210792062858
DOI https://dx.doi.org/10.2174/138161210792062858 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Surgical Management of Heart Failure
Current Cardiology Reviews COVID-19 in Children: A Narrative Review
Current Pediatric Reviews Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews High-pitch Dual-source CT Angiography before TAVI - the Value of ECG Gating
Current Medical Imaging Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research Re: ‘Re. Renal Function Impairment in Patients Undergoing Elective EVAR vs Elective Open Repair During Follow up Period: A Systematic Review of the Literature’
Current Vascular Pharmacology Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets Editorial: Neuronanomedicine - (Part II)
Current Medicinal Chemistry Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design How Do Microbubbles and Ultrasound Interact? Basic Physical, Dynamic and Engineering Principles
Current Pharmaceutical Design MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Current Management and Treatment of Cerebral Vasospasm Complicating SAH
CNS & Neurological Disorders - Drug Targets An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design